DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,046 filers reported holding DANAHER CORPORATION in Q3 2016. The put-call ratio across all filers is 0.17 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,678,076 | +7.4% | 6,772 | +4.0% | 0.09% | +11.7% |
| Q2 2023 | $1,562,880 | -14.0% | 6,512 | -9.7% | 0.08% | -16.3% |
| Q1 2023 | $1,817,208 | -4.7% | 7,210 | +0.3% | 0.09% | -8.0% |
| Q4 2022 | $1,907,308 | +2.8% | 7,186 | 0.0% | 0.10% | -4.8% |
| Q3 2022 | $1,856,000 | +0.5% | 7,186 | -1.4% | 0.10% | +12.9% |
| Q2 2022 | $1,847,000 | -13.6% | 7,286 | 0.0% | 0.09% | -6.1% |
| Q1 2022 | $2,137,000 | -7.5% | 7,286 | +3.8% | 0.10% | -1.0% |
| Q4 2021 | $2,310,000 | +4.9% | 7,021 | -2.9% | 0.10% | 0.0% |
| Q3 2021 | $2,202,000 | -7.9% | 7,234 | -18.8% | 0.10% | -5.7% |
| Q2 2021 | $2,391,000 | +13.4% | 8,911 | -4.9% | 0.11% | +9.3% |
| Q1 2021 | $2,108,000 | +1.0% | 9,366 | -0.3% | 0.10% | -6.7% |
| Q4 2020 | $2,088,000 | +2.9% | 9,398 | -0.3% | 0.10% | -5.5% |
| Q3 2020 | $2,029,000 | +4.8% | 9,422 | -13.9% | 0.11% | +4.8% |
| Q2 2020 | $1,936,000 | +15.4% | 10,946 | -9.7% | 0.10% | +2.9% |
| Q1 2020 | $1,678,000 | -9.8% | 12,121 | 0.0% | 0.10% | +14.6% |
| Q4 2019 | $1,860,000 | +6.2% | 12,121 | 0.0% | 0.09% | 0.0% |
| Q3 2019 | $1,751,000 | +1.0% | 12,121 | -0.1% | 0.09% | +3.5% |
| Q2 2019 | $1,733,000 | +8.2% | 12,128 | 0.0% | 0.09% | +14.7% |
| Q1 2019 | $1,601,000 | +28.7% | 12,128 | +0.5% | 0.08% | +19.0% |
| Q4 2018 | $1,244,000 | -20.1% | 12,064 | -15.7% | 0.06% | -1.6% |
| Q3 2018 | $1,556,000 | +15.0% | 14,319 | +4.4% | 0.06% | +8.5% |
| Q2 2018 | $1,353,000 | +84.8% | 13,709 | +83.4% | 0.06% | +78.8% |
| Q1 2018 | $732,000 | -47.9% | 7,474 | -55.1% | 0.03% | -50.0% |
| Q2 2017 | $1,406,000 | -23.0% | 16,664 | -22.0% | 0.07% | -22.4% |
| Q1 2017 | $1,826,000 | +14.5% | 21,352 | +4.2% | 0.08% | +13.3% |
| Q4 2016 | $1,595,000 | +48.9% | 20,490 | +49.9% | 0.08% | +47.1% |
| Q3 2016 | $1,071,000 | -80.8% | 13,667 | -77.6% | 0.05% | -79.4% |
| Q2 2016 | $5,577,000 | -8.2% | 60,929 | -4.9% | 0.25% | -9.5% |
| Q1 2016 | $6,074,000 | +6.5% | 64,036 | +1022.7% | 0.27% | -1.1% |
| Q4 2015 | $5,704,000 | +111.4% | 5,704 | -82.0% | 0.28% | +118.1% |
| Q3 2015 | $2,698,000 | +600.8% | 31,662 | +547.7% | 0.13% | +452.2% |
| Q2 2014 | $385,000 | -31.0% | 4,888 | -34.3% | 0.02% | -34.3% |
| Q1 2014 | $558,000 | -4.0% | 7,435 | -1.3% | 0.04% | -5.4% |
| Q4 2013 | $581,000 | +11.3% | 7,530 | 0.0% | 0.04% | 0.0% |
| Q3 2013 | $522,000 | +9.4% | 7,530 | 0.0% | 0.04% | +2.8% |
| Q2 2013 | $477,000 | – | 7,530 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |